AP NEWS

Luciole Medical Raises CHF 5.3 Million in Series A Financing for Novel Brain Monitoring Platform

September 17, 2018

ZÜRICH--(BUSINESS WIRE)--Sep 17, 2018--Luciole Medical AG announced today that it closed a CHF 5.3 million (EUR 4.7 million) Series A financing round. New investor SVC Ltd. (SVC Ltd. for Risk Capital for SMEs, a subsidiary of Credit Suisse), led the round with Blue Ocean Ventures, Investiere and B-to-V as co-investors with significant support from existing shareholder ZKB (Zürcher Kantonalbank). The company will use the funds to initiate commercialization of its minimally-invasive monitoring probe designed to measure blood oxygen levels in the brain, specifically for patients in intensive care units. In addition, the company will apply its platform toward the further development of its non-invasive patch that is designed to measure oxygen saturation and blood flow of brain tissue in patients undergoing surgery.

“This support from seasoned investors is a transformative step that will allow us to accelerate the development of our next-generation brain monitoring platform,” commented Dr. Philippe Dro, CEO of Luciole Medical. “Our goal is to commercialize these important clinical tools that enable physicians to rapidly access critical information on the oxygenation status of the brain.”

Brain oxygenation and blood flow are critical for brain function. Impaired oxygenation in the brain can rapidly lead to severe consequences such as cognitive decline, speech impairment, paralysis, coma and even death. Measuring these parameters in patients and during surgery is vital for the immediate diagnosis and treatment of the patient. Luciole Medical has developed a platform of next-generation devices to monitor these parameters. The technology measures oxygenated and de-oxygenated hemoglobin content in the brain as well as cerebral blood flow, thus giving precious information on tissue metabolism and brain function. The company has received the CE mark in 2016 for its minimally invasive probe for use in comatose patients following stroke or traumatic brain injury. Luciole Medical’s second product, a non-invasive patch, is currently under development and will be used in anesthesia and in other conditions where the brain may be exposed to desaturation.

About Luciole Medical Luciole Medical AG is developing a unique, next-generation platform of brain monitoring devices to rapidly provide important information allowing the proper diagnostic and monitoring of compromised oxygen supply conditions and complications. The company obtained the CE mark for a minimally invasive probe for ICU and is developing a patch for external measurement of brain oxygenation parameters. The Swiss-based private company is a spin out from the Swiss Polytechnic Institute and the University of Zürich. For more information, visit http://www.luciolemedical.ch

View source version on businesswire.com:https://www.businesswire.com/news/home/20180917005243/en/

CONTACT: Luciole Medical:

Dr. Philippe Dro, CEO

Phone: +41 43343 96 04

philippe.dro@luciolemedical.ch

or

Media requests:

Trophic Communications

Gretchen Schweitzer

Phone: +49 89 2388 7730

or

Dr. Jacob Verghese

Phone: +49 173 364 1607

verghese@trophic.eu

KEYWORD: EUROPE SWITZERLAND

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY HOSPITALS MEDICAL DEVICES PROFESSIONAL SERVICES FINANCE RESEARCH MEDICAL SUPPLIES SCIENCE

SOURCE: Luciole Medical

Copyright Business Wire 2018.

PUB: 09/17/2018 05:00 AM/DISC: 09/17/2018 05:01 AM

http://www.businesswire.com/news/home/20180917005243/en

AP RADIO
Update hourly